16.05.2014 Views

Patent It Yourself - PDF Archive

Patent It Yourself - PDF Archive

Patent It Yourself - PDF Archive

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

590 | <strong>Patent</strong> it YOURSELF<br />

N/A (Notice of Allowance), 183, 341,<br />

386, 389, 390<br />

passive citation of prior art prior to,<br />

429<br />

NASA declarations, 396<br />

National defense<br />

infringement by device used in, 425<br />

military inventions, 325, 339<br />

nuclear weapons, 102<br />

Naturally occurring phenomena, 15,<br />

96, 97, 98, 99–100<br />

design patents and, 10<br />

NDA. See Nondisclosure agreement<br />

(NDA)<br />

Negative doctrine of equivalents, 423<br />

New and unexpected result. See<br />

Unobviousness<br />

New matter, in patent application, 187,<br />

259, 276, 346, 348, 356, 365<br />

drawings and, 238, 386<br />

substitute specification and, 365<br />

New-use inventions, 95, 100, 107<br />

claims for, 231, 241<br />

unobviousness of, 110<br />

NIH (Not Invented Here) syndrome,<br />

310–311<br />

Non-Convention countries, 322, 325,<br />

328, 339<br />

Nondisclosure agreement (NDA)<br />

for building and testing, 49<br />

for consultants, 89<br />

for employees, 28, 175<br />

limitations on value of, 49<br />

for persons who see invention, 89<br />

during prosecution, 364<br />

for trade secret, 175<br />

for venture capitalist, 315<br />

for witnesses to documentation, 47<br />

Nonlinear thinking, 39–40<br />

Nonobviousness. See Unobviousness<br />

Non-patent Literature (NPL)<br />

on Information Disclosure<br />

Statement, 286, 287, 340<br />

on sample specification, 210<br />

search of, 143, 166–167<br />

Nonpublication Request (NPR), 26,<br />

183, 276, 278<br />

advantages and disadvantages, 276,<br />

278, 396<br />

in electronic filing, 274, 276, 285<br />

foreign filing and, 183, 274, 276, 278,<br />

320–321, 332<br />

offensive rights and, 339<br />

rescission of, 183, 278, 320–321, 332<br />

to recover for infringement, 426<br />

for trade secret, 175, 176<br />

See also Publication of patent<br />

application<br />

Notarization<br />

of notebook, 54<br />

of verified showing, 393<br />

Notebook, 49–54. See also<br />

Documentation of invention<br />

Notice of Abandonment, 394<br />

Notice of Allowability, 341, 389<br />

Notice of Allowance (N/A), 183, 341,<br />

386, 389, 390<br />

passive citation of prior art prior to,<br />

429<br />

Notice of Appeal, 392<br />

Notice of Draftsperson’s <strong>Patent</strong><br />

Drawing Review, 258, 355, 356<br />

Notice of <strong>Patent</strong> Expiration, 420<br />

Notice of <strong>Patent</strong> Term Adjustment, 389<br />

Notice of References Cited, 351, 354,<br />

356, 358<br />

Not Invented Here (NIH) syndrome,<br />

310–311<br />

Novelty, 10, 94, 95, 96, 102–107<br />

claim drafting and, 185, 226, 233,<br />

246, 250, 359<br />

with Jepson-type claims, 227<br />

whereby clause and, 229<br />

copyright and, 23<br />

discussed in specification, 185, 196,<br />

201, 209<br />

entered in notebook, 50, 51<br />

examiner’s determination of, 116<br />

marketability and, 80, 83, 173<br />

one-year rule and, 103<br />

in patentability flowchart, 114, 117<br />

patentability search and, 121, 122<br />

response to Office Action and, 346,<br />

359, 360, 365, 385<br />

scope of patent coverage and,<br />

154–155<br />

single document rule and, 107<br />

sources of supply and, 185<br />

three types of, 106–107<br />

See also Prior art<br />

NPL. See Non-patent Literature (NPL)<br />

NPR. See Nonpublication Request<br />

(NPR)<br />

Nuclear weapons, 102<br />

Nucleotide sequence. See Biotechnology<br />

sequence; DNA<br />

O<br />

OA. See Office Action (OA)<br />

OAPI (Organisation Africaine de la<br />

Propriété Intellectuelle), 320, 322<br />

Object code, 187, 188, 189<br />

Objections<br />

compared to rejections, 348–349<br />

to drawings, 183, 340, 347, 353, 355,<br />

356, 385–386<br />

initial, 183<br />

to specification, 183, 340, 347, 353,<br />

356<br />

“Objects,” avoiding reference to, 199<br />

Obviousness, 110–111<br />

by analogy, 110, 115<br />

discussion of prior art and, 198<br />

prima facie case of, 110, 383<br />

rejections based on, 359, 360,<br />

361–362, 363<br />

double patenting and, 348<br />

See also Unobviousness<br />

Offensive rights, 15, 16–17<br />

summary chart, 29, 30<br />

Office Action (OA), 183, 340–341<br />

availability to respond, 345<br />

deadlines for reply to, 342, 397<br />

dealing with, 357–365<br />

clear language issues, 363, 384–385<br />

See also Amendments<br />

by email, 284<br />

final, 341, 351, 390, 391, 394<br />

continuation application and,<br />

400, 402<br />

RCE and, 404<br />

First Action Interview Pilot<br />

Program and, 286, 341<br />

form paragraphs in, 347–348<br />

increased delays in receiving, 349<br />

mistakes in, 342, 343<br />

objections to drawings in, 183, 340,<br />

347, 353, 355, 356, 385–386<br />

objections to specification in, 183,<br />

340, 347, 353, 356<br />

obviousness rejections in, 348, 359,<br />

360, 361–362, 363

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!